Articles tagged with Chemotherapy
The study found that BAC proliferation correlated with HER2 but not EGFR expression, suggesting a potential role for combination therapies. Researchers hope to launch a clinical trial of HER2- and EGFR-blocker combination therapy in the treatment of BAC.
Two studies found that paclitaxel-based chemotherapy regimens and mini-transplants can help preserve ovarian function in younger patients. The paclitaxel regimen improved a woman's chance of regaining her ovarian function, while mini-transplants showed better results in preserving ovaries compared to high-dose chemo.
A new monoclonal antibody combination therapy has been found to be highly effective in treating chronic lymphocytic leukemia, with a remarkable 69% complete remission rate. The treatment, which combines two chemotherapy drugs with Rituximab, shows promising results across all age groups and stages of the disease.
A new study found that chemotherapy and radiotherapy together reduce surgery and removal of the voice box due to cancer recurrence. The combination treatment was associated with a significantly lower rate of surgeries compared to standard therapy or radiotherapy alone.
A new chemotherapy regimen combining docetaxel with cisplatin and 5-Fluorouracil has been shown to significantly improve survival rates in late-stage stomach cancer patients. The study found a nearly 80% higher chance of tumor shrinkage and a reduced risk of cancer growth.
Researchers at Stanford have shown positive results with a new chemotherapy combination, Iressa and FOLFOX, in treating colon cancer. The treatment has been effective in shrinking tumors by up to 75% in patients who had never received chemotherapy before.
A new DNA array technology test has identified differences in gene patterns that predict which breast cancer patients will respond to chemotherapy. The study, led by Dr. Jenny Chang at Baylor College of Medicine, found that 88% of genes were correctly classified, allowing for personalized treatment strategies.
The GELA study reveals that MabThera plus CHOP improves three-year event-free survival by 18% and overall survival by 11%, with no increased toxicity. This breakthrough treatment offers a potential cure for aggressive NHL, which affects 55% of the 1.5 million people worldwide suffering from non-Hodgkin's lymphoma.
Researchers found that gefitinib can slow lung cancer tumor recurrence when used as maintenance therapy following chemotherapy. The study suggests that gefitinib may keep cancer cells dormant for a period of time.
Researchers at Memorial Sloan Kettering Cancer Center found that targeted therapy erlotinib caused dramatic tumor regressions in some patients with BAC, particularly those who never smoked. The treatment was effective in 25% of patients with advanced BAC, offering a new approach to managing this disease.
A new radiotherapy strategy, hyperfractionated accelerated radiotherapy (HART), has been shown to improve survival rates for lung cancer patients. In a phase III multi-site study, chemotherapy followed by HART resulted in a median survival of 21 months, compared to 12 months with standard radiation therapy.
Researchers at M. D. Anderson Cancer Center found that combining Gleevec with chemotherapy resulted in significant drops in PSA levels in some patients, indicating potential therapeutic benefit. The combination therapy showed slow but sustained responses, suggesting a valid target in prostate cancer treatment.
Researchers at the University of Texas M. D. Anderson Cancer Center have developed a gene screen that can accurately predict which chemotherapy regimens will be effective for patients with newly diagnosed breast cancer. The test is 75% accurate in forecasting complete eradication of cancer, eliminating the need for trial and error.
Bevacizumab significantly extends survival time for metastatic colorectal cancer patients by shrinking tumors and inhibiting tumor growth. The study showed a median survival increase of five months compared to standard chemotherapy alone, with significant delays in cancer progression.
A Phase II study shows that administering ADVEXIN, a p53 drug, directly to tumors can improve the results of neoadjuvant chemotherapy in locally advanced breast cancer. The treatment resulted in dramatic tumor shrinkage and minimal residual tumor cells.
USC researchers have identified a protein fragment, PEP, that can increase the effectiveness of chemotherapy drugs against tumors. By making tumor blood vessels more permeable, PEP allows for better drug uptake and increased chemotherapy efficacy.
Researchers discover that ovarian tumor cells can 'switch back' to a normal state, making them vulnerable to chemotherapy. This finding represents a crucial step toward the discovery of new anti-cancer drugs.
Researchers treated 18 patients with lung nodules using radiofrequency ablation, achieving a 97% destruction rate. The treatment was found to be short-lasting and manageable, with most complications resolved within a week.
A Phase II study found that the DVd regimen showed a high response rate of 88%, with 12% achieving complete response. The treatment was well-tolerated, with the most common Grade 3 or 4 toxicity being palmar-plantar erythrodysesthesia. Improved patient education and prevention measures reduced toxicity incidence.
Researchers at McGill University discovered a genetic mutation, MTHFR variant, that predicts better response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer patients. The study found 26 out of 43 patients with the variant responded well to chemotherapy.
Researchers at Cedars-Sinai Medical Center found that patients with hereditary BRCA-associated ovarian cancer respond better to chemotherapy, leading to improved survival. The study suggests that platinum-based chemotherapy may be more effective for these patients, and this finding may enable physicians to better plan treatment.
Researchers found that ovarian cancer cells produce collagen VI, which remodels their environment to make them more resistant to chemotherapy. This could lead to new therapeutic interventions to overcome chemotherapy resistance and improve survival rates for women with ovarian cancer.
Researchers identified 124 genes whose changes in expression differed depending on the treatment regimen, providing new clues on how medications work and how cancer cells protect themselves. The study's findings will help design more rational and effective ways to use drugs for deadly childhood leukemia.
The article discusses the relationship between natural and synthetic substances in relation to human health. Key findings include the difficulty of synthesizing complex natural compounds and the potential for modification by synthetic chemists to enhance medicinal properties.
A new study found that strengthening upper leg muscles does not protect against knee osteoarthritis and may even worsen it in people with certain knee conditions. Researchers also discovered that one-third of cancer patients who died received chemotherapy in their last six months of life.
Researchers at M.D. Anderson Cancer Center found that the novel proteasome inhibitor PS-341 works synergistically with certain chemotherapy agents but not others, suggesting a critical role of sequence in treatment efficacy. The findings have important implications for future clinical trials and potential cancer treatments.
Researchers at Mayo Clinic have discovered that thalidomide can effectively delay the progression of early-stage multiple myeloma in some patients. In a phase II clinical trial, approximately 80% of patients remained progression-free after one year and 63% were still free from disease progression after two years.
According to a study by the National Cancer Institute, approximately 10 million women in the US aged 35-79 are eligible for tamoxifen due to high breast cancer risk. After analyzing age-related benefits and risks, researchers found that younger women (40-59) have a higher likelihood of benefiting from the drug.
Researchers have developed a novel screening technique that quickly identifies chemical compounds active only against certain cancer-causing genes and proteins. This approach opens the door to custom-tailoring chemotherapy and may lead to more effective treatments for specific types of cancer.
A new study led by Queen's University aims to increase the sensitivity of prostate cancers to anti-cancer drugs using nitroglycerine. Researchers hope to develop a better understanding of how prostate cancer cells become resistant to chemotherapy, with potential applications for other cancers such as breast cancer.
A Phase III randomized trial found that a combination of vinorelbine and gemcitabine did not improve overall and progression-free survival in elderly NSCLC patients. However, the study suggests that certain chemotherapy combinations, particularly cisplatin-based regimens, may be more effective than single-agent therapy. The results als...
Researchers have discovered a new six-drug chemotherapy regimen that significantly improves the overall survival rate of Ewing's sarcoma patients to 72% without metastases. The treatment has become routine care for patients with localized disease and has marked a substantial improvement in survival rates.
Researchers are working towards individualized treatments using DNA chip technology to analyze gene expression and detect host genetic polymorphisms. This approach aims to optimize drug selection and doses at a molecular level, reducing toxicity and improving patient outcomes for childhood acute lymphoblastic leukemia.
A new treatment, interleukin-11 (IL-11), has shown early promise in reducing the risk of infection in patients undergoing chemotherapy for blood cancer. Patients who received IL-11 experienced significantly fewer cases of bacterial infections compared to those who received a placebo.
A study on breast cancer treatment found that many women do not receive adjuvant chemotherapy as recommended, with age being a significant factor. In contrast, women with known heart disease are at high risk of future heart events but often lack preventive treatments, highlighting the need for better care coordination.
The study found a significant discrepancy between recommended adjuvant chemotherapy and actual use, with younger women more likely to receive treatment. Overall, only 29% of women received chemotherapy, highlighting the need for re-evaluation of current NIH guidelines.
Two trials found that adjuvant chemotherapy improved recurrence-free survival by 8-11% and overall survival by 5-9%, primarily benefiting patients with unrecognized residual disease. These findings suggest that adjuvant chemotherapy may be most effective in patients with non-optimal surgical staging.
A novel treatment approach combining surgery and intraperitoneal hyperthermic chemotherapy (IPHC) has shown significant promise in improving survival rates for patients with peritoneal carcinomatosis. The study found that selected patients may benefit from improved quality of life and extended survival.
Researchers have discovered that combining Avastin with chemotherapy provides superior treatment for advanced colorectal cancer, increasing median survival by 8.3 months and response rates. The study's findings suggest a more effective and less toxic option for patients with this devastating form of cancer.
Researchers studied rapamycin's molecular action and found it blocks tumor-cell growth by triggering stress responses, stopping cell proliferation. The study identified a new type of gene regulation involving the target of rapamycin (TOR) protein.
A clinical trial showed that dose-dense chemotherapy regimens improved disease-free and overall survival in breast cancer patients by 7-12 percentage points. The regimens, which involve giving drugs more frequently, resulted in fewer side effects and less neutropenia compared to conventional therapy.
The CALGB 9741 study found significant improvements in disease-free survival and overall survival for women with axillary node-positive operable breast cancer treated with dose-dense chemotherapy regimens. The study showed a 26% proportional reduction in risk of recurrence and improved quality of life with dose-dense therapy.
Researchers at Dana-Farber Cancer Institute found that combination therapy of cytarabine, daunorubicin, and Mylotarg achieved complete remission in 83% of evaluable participants. The treatment was well-tolerated, with no significant increase in side effects.
Researchers at Dana-Farber Cancer Institute identified a gene signature that distinguishes leukemia patients who can be cured with intensive chemotherapy from those who require bone marrow transplantation. Patients with high HOX11 expression survived for three years and were most likely cured, while those without it had poorer outcomes.
A new 'designer' drug has shown activity in treating acute myeloid leukemia (AML), with 13 of 15 patients experiencing reductions in abnormal white blood cell counts. The experimental compound targets a specific genetic flaw, offering a more targeted approach to conventional chemotherapy drugs.
A phase II clinical trial shows the oral combination of thalidomide and dexamethasone reduces tumor size by 50% or more in 64% of newly diagnosed multiple myeloma patients. This treatment alternative offers a promising solution to chemotherapy's side effects, including nausea, vomiting, and hair loss.
A new strategy in cancer treatment involves using genetic information to guide drug delivery, allowing for more targeted and efficient treatments. The approach uses nucleic acid-triggered catalytic drug release, recognizing and responding to unique cancerous sequences to deliver potent anticancer drugs.
Early results of North American trials of oxaliplatin show a 70% delay in tumour progression and significant improvement in symptoms for patients with advanced bowel cancer. The US FDA has approved the drug for use in these patients.
A new trial shows that high-dose chemotherapy has no significant benefits for women with severe breast cancer. However, molecularly targeted drugs in combination with chemotherapy show promising results.
Research by Dr Anne Chantal Braud and her team has shown that older women with breast cancer can tolerate powerful medication, contradicting initial expectations. The study examined the effects of surgery, radiotherapy, chemotherapy, and hormone therapy on 179 women over 70 years old.
A study by Dr. Tony Mok and his team investigates the potential benefits of Chinese herbal medicine in reducing chemotherapy-induced toxicity in breast and colon cancer patients. Early results show a moderate reduction in symptoms, paving the way for further research into this alternative treatment approach.
A new phase III multi-national European trial involving 618 patients with advanced non small-cell lung cancer found that cisplatin and paclitaxel improved survival rates compared to carboplatin and paclitaxel. The study suggests that cisplatin-based chemotherapy remains the preferred standard treatment for lung cancer in Europe.
Healthy, nondividing cells have a biochemical switch that triggers apoptosis when inactivated by deamidation of Bcl-xL protein. This discovery suggests that tumor cells with the same switch may be resistant to chemotherapy drugs.
A new clinical trial is investigating the combination of high-dose calcitriol and docetaxel in treating advanced prostate cancer, with the goal of reducing PSA levels by 50% or more. The study builds on promising preliminary results from a previous Oregon Health & Science University trial.
A review highlights the association between excess body weight and increased cancer risk, particularly in colon, breast, endometrium, oesophagus, and kidney. The study suggests that alterations in hormone metabolism may play a role in this link, emphasizing the importance of weight management for cancer prevention.
A study found that St. John's wort significantly lowers blood levels of irinotecan's active metabolite SN-38 by 42%, decreasing detoxification and reducing overall antitumor activity. Patients receiving chemotherapeutic treatments with St. John's wort may need to increase drug dosage.
A new study from the International Collaborative Ovarian Neoplasm (ICON) Collaborators found that paclitaxel plus carboplatin produces similar effectiveness to other treatments for women with ovarian cancer, but with more serious side effects. Carboplatin may be considered a preferred treatment option due to its better toxicity profile.
A new treatment approach using cisplatin/epinephrine gel has shown significant promise in treating advanced head and neck cancer. The study found that 29% of patients experienced tumor responses, with 19% achieving complete responses.
A new study has shown that patients with mesothelioma, a cancer caused by asbestos exposure, can survive for up to 13-14 months when treated with the drug combination of pemetrexed and carboplatin. This is an improvement over previous treatments, which only offered a six-to-eight-month survival rate.
Research suggests that African-Americans with colon cancer fare equally well when receiving the same treatment as white patients, dispelling long-held theories about innate biological differences. The study found no significant disparities in survival rates between the two groups five years after treatment.